Ventria Bioscience and University of Southern California Awarded Grant to Develop a Fusion Protein for the Treatment of Diabetes

Published: Feb 12, 2013

FORT COLLINS, Colo.--(BUSINESS WIRE)--The National Institutes of Health has awarded a Small Business Innovation Research (SBIR) grant to Ventria Bioscience and the University of Southern California (USC), with the goal of developing a cost-effective method for producing clinical-grade proinsulin-transferrin (ProINS-Tf) using Ventria Bioscience’s ExpressTec recombinant expression system. ProINS-Tf is a fusion protein between proinsulin and transferrin and has been shown to exhibit enhanced, sustained, hypoglycemic efficacy in vivo compared to therapeutic insulin, making it a novel candidate treatment for diabetes.

Back to news